G Jerusalem

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

G. Jerusalem, P. Rigo, G. Fillet, 1999, Blood.

PET scan imaging in oncology.

R. Hustinx, G. Jerusalem, G. Fillet, 2003, European journal of cancer.

Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.

G. Jerusalem, P. Rigo, G. Fillet, 1999, Nuclear medicine communications.

European inter-institutional impact study of MammaPrint.

D. Generali, G. Jerusalem, J. Klaase, 2014, Breast.

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

R. Hustinx, G. Jerusalem, P. Rigo, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.

R. Hustinx, G. Jerusalem, G. Fillet, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.

G. Jerusalem, P. Rigo, G. Fillet, 2001, Haematologica.